Announcements Trials
Browse Landscape

Phase

Phase 3 11Phase 2 5Phase 2/3 2

Status

Completed 5

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Myeloid 2Plasma cell 1

Conditions

Mastocytosis 2Recurrence 1Multiple Myeloma 1Gastro-intestinal Stromal Tumours 1Gastro Intestinal Stromal Tumor 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × masitinib × Clear all
NCT00866138 2019-12-03

Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3

AB Science

Phase 2 Completed
24 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT00831974 2018-12-11

Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis

AB Science

Phase 2 Completed
23 enrolled
Myeloid

Mastocytosis

NCT00998751 2018-12-11

Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)

AB Science

Phase 2 Completed
30 enrolled

Gastro-intestinal Stromal Tumours

NCT01506336 2018-12-11

Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib

AB Science

Phase 2 Completed
44 enrolled

Gastro Intestinal Stromal Tumor

NCT01266369 2018-12-10

Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation

AB Science

Phase 2 Completed
21 enrolled
Myeloid

Mastocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡